We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Prokarium Acquires Key Oral Vaccine Technology from Emergent BioSolutions

News   Jul 10, 2012

 
Prokarium Acquires Key Oral Vaccine Technology from Emergent BioSolutions
 
 
Advertisement
 

RELATED ARTICLES

CAR T-Cell Therapy Shows Promising Early Results in Children With Neuroblastoma

News

A novel CAR T-cell therapy has shown promising early results in children with neuroblastoma, a rare form of childhood cancer. Twelve children with relapsed or refractory neuroblastoma were treated as part of a Phase I clinical trial.

READ MORE

Therapeutic Cancer Vaccine Demonstrates Good Safety and Efficacy in Preclinical Study

News

A checkpoint inhibitor vaccine known as PD1-Vaxx was shown to be safe and effective in a colon cancer syngeneic animal model.

READ MORE

Oxford's COVID-19 Vaccine Has 70% Efficacy Rate

News

There are now over 170 teams of researchers working to develop a vaccine for protection against COVID-19. Over the last few weeks, a number of groups shared interim analysis data on candidates that have reached Phase III clinical testing. The latest addition is the University of Oxford – in collaboration with the pharmaceutical company AstraZeneca – who today announce an efficacy of 70.4% for the candidate, ChAdOx1 nCoV-2019.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Biopharma Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE